Pixium Vision will be attending the Virtual Growth Conference 2022 announced by Maxim Group LLC and hosted by M-Vest at 07:00 from March 28th to 30th, 2022.


Vision will participate in the 2022 Virtual Growth Conference announced by Maxim Group LLC and hosted by M-.


From March 28th to 30th

Paris, France,




202 202


– 7am CET

– Pixium Vision SA (Euronext Growth Paris-FR0011950641; Mnemo: ALPIX) is a bioelectronics company developing an innovative bionic vision system that enables blind patients to live more independently today. Pixium Vision CEO Lloyd Diamond announces at Maxim Group LLC’s 2022 Virtual Growth Conference hosted by M-Vest, EDT from 9am to 5pm from March 28th to 30th / 3:00 pm Participate in the 23:00 CET.

Register here to attend the presentation.

At this virtual conference, investors will hear presentations from leaders in various sectors such as biotechnology, clean energy, electric vehicles, financial services, fintech and SIIC, games and entertainment, service health, and information technology in the health sector. I can. , Infrastructure, sea shipping and technology / media / telecom. The agenda of this meeting: company presentations, informal discussions, roundtables, and live Q & A sessions with the CEO. It will be moderated by an analyst at Maxim Research.

This conference will be broadcast live on M-Vest. To participate, please register to become a member of M-Vest.

Click here to book a spot.






Create a world of bionic vision so that people who have lost sight can restore vision and gain autonomy. Pixium Vision’s bionic vision system is associated with the duration of surgery and rehabilitation. Prima System’s wireless photoelectrogenic subretinal microimplant is in clinical trials in patients who initially lose vision due to retinal degeneration due to dry age-related macular degeneration (dry AMD). .. Pixium Vision works closely with academic partners and some of the world’s most prestigious vision research institutes. For example, Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) Barcelona, ​​University Hospital in Bonn, UPMC in Pittsburgh (Pennsylvania, USA). We are ENISO 13485 certified and have been certified as an “Innovative Company” by Bpifrance.

Forward-Looking Statements This press release contains forward-looking statements. We believe our forecasts are based on reasonable assumptions, but these forward-looking statements carry a lot of risk and uncertainty and actual results may differ materially from those forecasts. there is. For more information on risks and uncertainties in which our actual performance, financial position, performance or performance may differ from those contained in our forward-looking statements, please see our FY2021 Risk Factors section. please refer to. Annual financial reports and other documents that we submit to AMF. It is available on the AMF website (www.amf-france.org) or on our website.

For more information:


follow me





contact address



Providing Nonhoff

Chief financial officer

[email protected]

+33 1 76 21 47 68



LifeSci Advisors

Sophie Baumont

[email protected]

+33 6 27 74 74 49

Investor public relations

LifeSci Advisors

Guillaume van Rentelgem

[email protected]

+41 76 735 01 31